Olimel N9E/PeriOlimel N4E

Olimel N9E/PeriOlimel N4E Drug Interactions

Manufacturer:

Baxter Healthcare

Distributor:

Baxter Healthcare
/
Firma Chun Cheong
Full Prescribing Info
Drug Interactions
No interaction studies have been performed.
OLIMEL/PERIOLIMEL must not be administered simultaneously with blood through the same infusion tubing because of the possibility of pseudoagglutination.
The lipids contained in this emulsion may interfere with the results of certain laboratory tests (for example, bilirubin, lactate dehydrogenase, oxygen saturation, blood haemoglobin) if the blood sample is taken before the lipids are eliminated (these are generally eliminated after a period of 5 to 6 hours without receiving lipids).
Precipitation of ceftriaxone-calcium can occur when ceftriaxone is mixed with calcium-containing solutions in the same intravenous administration line. Ceftriaxone must not be mixed or administered simultaneously with calcium-containing intravenous solutions, including OLIMEL/PERIOLIMEL, through the same infusion line (e.g., via Y-site). However, ceftriaxone and calcium-containing solutions may be administered sequentially of one another if the infusion lines are thoroughly flushed between infusions with a compatible fluid (see Precautions and Incompatibilities under Cautions for Usage).
OLIMEL/PERIOLIMEL contains vitamin K, naturally present in lipid emulsions. The amount of vitamin K in recommended doses of OLIMEL/PERIOLIMEL are not expected to influence effects of coumarin derivatives.
Due to the potassium content of OLIMEL/PERIOLIMEL, special care should be taken in patients treated with potassium-sparing diuretics (e.g. amiloride, spironolactone, triamterene), angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor antagonists, or the immunosuppressants tacrolimus or cyclosporine in view of the risk of hyperkalaemia.
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Sign up for free
Already a member? Sign in